BACKGROUND: Surveillance has been recommended more frequently as a postorchiectomy management option for men with early stage nonseminomatous germ cell tumor (NSGCT) of the testicle. It is unknown how contemporary treatment patterns reflect these recommendations. METHODS: Data from the National Cancer Database were extracted on all men who were diagnosed with clinical stage (CS) IA or CSIB NSGCT between 2004 and 2013. Temporal trends in the use of chemotherapy, retroperitoneal lymph node dissection (RPLND), and surveillance were measured; and multivariable logistic regression was used to analyze the association of patient and clinical covariates with use of surveillance. RESULTS: Of the 4080 men with CSIA NSGCT, 70%, 17%, and 13% received surveillance, RPLND, and chemotherapy, respectively. Surveillance increased in this group from 65% (2004)(2005) to 74% (2012-2013: adjusted odds ratio, 1.50; 95% confidence interval, 1.14-1.98; P 5.004). Of the 2580 men who had CSIB NSGCT, 46%, 20%, and 34% received surveillance, RPLND, and chemotherapy, respectively. In this group, 48% of men underwent surveillance in the years 2004 to 2005 and 2012 to 2013 (adjusted P 5.8). Upon multivariable analyses, higher income and the oldest age quartile were associated with increased odds of surveillance among men with CSIA NSGCT (both P <.050). Hispanic men with CSIB NSGCT were more likely to receive surveillance compared with non-Hispanic white men (P 5.001). CONCLUSIONS: Nearly 75% of men with CSIA NSGCT and nearly 50% of men with CSIB NSGCT received surveillance in 2012 and 2013. The likelihood of receiving surveillance increased from 2004 through 2013 for men with CSIA NSGCT but was unchanged for men with CSIB. Cancer 2017;123:245-52.
INTRODUCTION
The incidence of testicular germ cell tumors has increased in recent years and is expected to account for over 8000 new cancer cases in 2016 in the United States. 1, 2 Of these, nearly one-half are expected to be nonseminomatous germ cell tumors (NSGCTs). 1 For men with early clinical stage (CS) IA or CSIB NSGCT, clinical guidelines describe surveillance, nerve-sparing retroperitoneal lymph node dissection (RPLND), or cisplatin-based chemotherapy as management options after orchiectomy, with surveillance preferred for patients with no lymphovascular invasion (CSIA). 3, 4 Surveillance is preferred for patients with CSIA NSGCT because of their relatively low rates of recurrence (approximately 20%) and the potential risks associated with either chemotherapy, such as secondary malignancy and cardiovascular disease, or primary RPLND. [5] [6] [7] Surveillance spares nearly 70% of men with clinical stage I NSGCT any active treatment after orchiectomy without compromising cancer-specific survival. 8 For these reasons, a 2008 European consensus conference recommended surveillance as a first-line option for CSIA and as a possible option for select men when lymphovascular invasion is present (CSIB). 9 With the possibility of reduced morbidity, improved cost effectiveness, and similar long-term cancer-specific survival compared with chemotherapy and RPLND (range, 99%-100%), it is believed that the use of surveillance for early stage NSGCT has increased in recent years. 10, 11 Although approximately 41% of patients underwent orchiectomy alone in a population-based cohort from 1999, 12 more recent trends are unknown. We undertook the current study to evaluate temporal trends in the management of early stage NSGCT in a large, contemporary US hospital-based cancer registry and to identify the patient and clinical factors associated with surveillance.
MATERIALS AND METHODS

Data Source
Our cohort was derived from the National Cancer Data Base (NCDB) testicular cancer participant user file for the years 2004 through 2013. The NCDB is comprised of >1500 hospitals with cancer programs accredited by the American College of Surgeons' Commission on Cancer and the American Cancer Society, and it captures approximately 71% of all testicular cancers diagnosed in the United States across a diverse geographic area. 13 
Patients
We relied on the International Classification of Disease for Oncology, third edition (ICD-O-3), to identify men who were diagnosed with NSGCT based on histologic analysis of orchiectomy specimens, which included codes 9065 through 9102 (n 5 22,703). Only men who received treatment at facilities that contributed data each year of the study period were included (n 5 18,276). We included those who had with clinically localized testicular cancer (cN0/cNx and cM0; n 5 7698). We also focused our analysis on men who were potential candidates for surveillance after orchiectomy by limiting our analysis to men with CSIA (American Joint Committee on Cancer [AJCC] pathologic T1 [pT1]) or CSIB (AJCC pT2-pT4) NSGCT (n 5 7100). 3 We included only men who had information available on postorchiectomy treatment (n 5 6789). We excluded any patient who had received radiation (n 5 34). Finally, we also excluded men who were missing data on the timing of chemotherapy (n 5 95) if it was received.
Data regarding surveillance (S) stage were available for a limited number of patients. Because surveillance is generally not appropriate in men who have positive postorchiectomy tumor markers, we analyzed temporal treatment trends in men who had documented S0 NSGCT (n 5 944) separately for comparison with our entire cohort.
Independent Variables
Several independent variables were analyzed for their association with the use of surveillance. Year of diagnosis was clustered and considered as a categorical variable. Embryonal histology was defined using the ICD-O-3 histology code 9070. Race and ethnicity were combined into 1 categorical variable divided into non-Hispanic white, nonHispanic black, Hispanic, and other/unknown. Age was analyzed as a categorical variable based on the median age and interquartile range.
Additional patient characteristics, including DeyoCharlson comorbidity index, 14 
Defining Outcomes
Our main outcome was postorchiectomy surveillance. We defined postorchiectomy treatment as RPLND if patients had pathologic data on lymph nodes examined or were designated as "lymph node dissection" (excluding "lymph node aspiration"). The NCDB does not provide information on the date of RPLND receipt. If chemotherapy was received by patients who underwent RPLND, then RPLND was still considered the treatment. Postorchiectomy chemotherapy was defined as chemotherapy received within 60 days of orchiectomy and no RPLND. A cutoff of 60 days was selected to delineate between patients who received primary chemotherapy and those who likely received chemotherapy after a recurrence while on surveillance. Delaying primary chemotherapy > 60 days would be unusual, and recurrence rates for surveillance in that time frame are minimal: 1% (13 of 1226 patients) in 1 population-based study and 0% (0 of 170 patients) in another institutional series. 15, 16 Thus, surveillance was defined as no RPLND or chemotherapy or no RPLND and chemotherapy >60 days after orchiectomy. The breakdown of men who received chemotherapy and surveillance or underwent RPLND based on our definitions was analyzed in a sensitivity analysis.
The NCDB records overall survival for each patient based on living vital status and date of last follow-up after diagnosis of NSGCT. Overall survival was analyzed in patients based on postorchiectomy treatment.
Statistical Analyses
Unadjusted temporal trends in postorchiectomy treatment and descriptive characteristics of men with CSIA and CSIB NSGCT were documented. Pearson chi-square analyses were used to compare changes in the proportion of men who received surveillance, RPLND, or chemotherapy based on year of diagnosis.
Multivariable logistic regression analyses were used to identify independent variables associated with surveillance. To account for variability between treatment facilities (n 5 623), we adjusted for clustering of patients within treatment facilities. 17 Kaplan-Meier analyses were
Original Article used to determine overall survival based on clinical stage and treatment, and log-rank tests were used to compare survival based on treatment. All statistical tests were conducted using Stata 13.0 (Stata Corporation, College Station, Tex), and a 2-sided P value < .05 was considered significant for all analyses.
RESULTS
Patient Characteristics
Our final cohort consisted of 4080 men with CSIA NSGCT and 2580 men with CSIB NSGCT (Table 1) . Among men with documented normal serum tumor markers (S0), 615 had CSIA and 329 had CSIB tumors.
The median (interquartile range) follow-up for all patients was 45.0 months (interquartile range, 25.1-69.0 months) and did not differ based on clinical stage or treatment.
Most men were diagnosed in the later years of our study period (Table 1) . White race represented 77% of men with CSIA tumors and 78% of men with CSIB tumors. Patients with any embryonal histology comprised 14% and 27% of men with CSIA and CSIB NSGCT, respectively. Most men had private insurance (81% of men with CSIA and 83% of men with CSIB NSGCT).
For men who had CSIA NSGCT, postorchiectomy management rates were 70% surveillance, 17% RPLND, and 13% chemotherapy (Table 1 ). For those who had CSIB NSGCT, the postorchiectomy management rates were 46% surveillance, 20% RPLND, and 34% chemotherapy.
Temporal Treatment Trends
For men with CSIA or CSIB NSGCT, the overall use of surveillance was 58% in 2004 and 2005 and 64% in 2012 and 2013 (P 5 .009). RPLND use decreased from 22% to 14% (P < .001), and chemotherapy was stable between 20% and 22% (P 5 .2).
For men with CSIA NSGCT, the use of surveillance increased from 65% (2004) (2005) to 74% (2012-2013; P < .001) (Fig. 1a) , receipt of RPLND decreased from 22% to 14% (P < .001), and receipt of chemotherapy remained stable (from 14% to 13%; P 5 .7). Considering patients who had documented normal serum tumor markers (S0) and CSIA NSGCT, the use of surveillance increased from 67% (2004-2009) to 77% (2012-2013), although this was not a statistically significant difference (P 5 .106) (Fig. 2a) . The rate of RPLND remained stable at 16% (P 5 .9), and receipt of chemotherapy decreased from 17% to 8% (P 5 .016)
For men with CSIB NSGCT, the use of surveillance was 48% in the years 2004 to 2005 and 2012 to 2013 (P 5 .9) (Fig. 1b) , receipt of RPLND decreased from 22% to 16% (P 5 .017), and receipt of chemotherapy increased from 30% to 37%, although this was not a statistically significant difference (P 5 .052). Considering patients with documented normal serum tumor markers (S0) and CSIB tumors, the use of surveillance decreased from 48% (2004-2009) to 43% (2012-2013); however, this was not a statistically significant difference (P 5 .6). The rates of RPLND (26%-25%; P 5 .9) (Fig. 2b) and chemotherapy (26%-32%, P 5 .5) did not change significantly over time in this group. For CSIB NSGCT, later years of diagnosis were not associated with changes in the odds of surveillance (P 5 .8). Hispanic men were more likely to receive surveillance compared with non-Hispanic white men (OR, 1.59; 95% CI, 1.21-2.08; P 5 .001). NSGCTs classified as pT3 or pT4 were associated with a decreased odds of surveillance compared with pT2 NSGCTs (OR, 0.44; 95% CI, 0.32-0.68; P < .001).
Kaplan-Meier Analyses
Kaplan-Meier analyses revealed the 5-year and 10-year overall survival rates for each pathologic stage based on treatment ( Table 3 ). The 5-year and 10-year survival rates for men who received surveillance were 97% and 94%, respectively, for those with CSIA NSGCT and 97% and 96%, respectively, for those with CSIB NSGCT. Logrank tests revealed no differences in survival based on management for CSIA NSGCT (P 5 .064) or CSIB NSGCT (P 5 .4).
Chemotherapy Receipt Among Men who Underwent RPLND and Surveillance
Given our definitions for each initial management strategy, for some men who received chemotherapy, it was not considered their initial treatment if they had not received it within 60 days of orchiectomy or if they also underwent RPLND. In total, 1512 of 2063 men (73%) who received chemotherapy received it within 60 days of orchiectomy. Of the men who underwent RPLND (n 5 1179), 1104 (94%) had at least 5 lymph nodes examined, and 216 (19%) received any chemotherapy. The median time (interquartile range) until chemotherapy receipt in the RPLND group was 67.5 days (interquartile range, 27-101 days).
Of the men who received initial surveillance (n 5 4068), 434 (11%) received chemotherapy, and the median (interquartile range) time until chemotherapy receipt was 84.5 days (interquartile range, 69-114 days). The proportion of men who underwent RPLND or surveillance and received any chemotherapy did not differ Abbreviations: CI, confidence interval; OR, odds ratio. a Multivariable logistic regression analysis was used to evaluate the association of covariates with surveillance as primary management among men with localized nonseminomatous germ cell tumor of the testicle. The model was adjusted for clustering based on treatment facility. In total, 4080 men with clinical stage IA and 2580 clinical stage IB nonseminomatous germ cell tumor of the testicle were analyzed. b This P value indicates a significant difference.
significantly by year of diagnosis (P 5 .7 and P 5 .8, respectively). If all men who were considered surveillance patients and received chemotherapy were classified as chemotherapy recipients, then the overall use of surveillance would have decreased from 61% to 55%.
DISCUSSION
In recent years, there have been increasing recommendations for the use of surveillance for men with early stage, localized NSGCT. 8, 9 Data from the NCDB indicate that nearly 75% of men with CSIA NSGCT and nearly 50% of those with CSIB NSGCT received surveillance in the years 2012 and 2013, and the odds that men with CSIA NSGCT would receive surveillance increased by 50% since the years 2004 to 2005.
One population-based study of a 1999 cohort demonstrated that the use orchiectomy alone as treatment for localized NSGCT was 41%, 12 which was an increase from another report from the early 1990s. 18 The overall rate of surveillance in our cohort was 64% in 2012 and 2013. It is noteworthy that the rate of surveillance was much higher for men who did not have lymphovascular invasion (CSIA or AJCC pT1; 74%) compared with those who did have lymphovascular invasion or more advanced pT classification (CSIB or AJCC pT2-pT4; 48%) in the years 2012 and 2013. In addition, adjusted ORs demonstrated a temporal increase in surveillance only for men with CSIA NSGCT and not for those with CSIB NSGCT. Among patients who had any CSI NSGCT managed with initial surveillance, recurrence rates were from 44% to 50% in men with lymphovascular invasion and only 14% in men without lymphovascular invasion. 8, 19 Thus, the higher and increasing rates of surveillance for CSIA compared with CSIB may reflect greater use of risk-adapted management based on lymphovascular invasion. 20, 21 Among men who had CSIA NSGCT, increased income and a larger population within the patient's county were correlated with higher use of surveillance. It is not clear whether these associations were patient-driven, physician-recommended, or related to other factors, such as surveillance compliance. The rates of surveillance noncompliance appear to vary widely between studies. Evidence on risk factors for noncompliance and its ultimate effect on cancer mortality is minimal, requiring future study. 22 It is noteworthy that the recent increases in the incidence of NSGCT have been most pronounced among Hispanic men, 1 and nonwhite race is associated with worse cancer-specific survival. 23 In our cohort, Hispanic men with CSIB NSGCT were more likely to receive surveillance compared with white men. A recent NCDB study analyzing management trends for clinical stage I testicular seminoma demonstrated similar findings. 24 Given the limitations in the definitions of our outcome variables, it was impossible to determine the reason for this association.
In a report from the Surveillance, Epidemiology, and End Results (SEER) database, the rate of RPLND after orchiectomy was 18% in the years 2004 through 2006, which was less than one-half the rate observed in the years 1988 through 1995. 25 Our estimates of RPLND use in the years 2004 and 2005 were slightly higher than those reported in SEER. This is likely because of the composition of NCDB facilities, the majority of which are largevolume or academic comprehensive cancer programs. 26 However, our data noted a continued, significant decline in RPLND use for men with both CSIA and CSIB NSGCT. This decline may reflect the increased use of initial surveillance to minimize treatment-related morbidity, or it could represent decreased enthusiasm for primary RPLND because of concerns about higher recurrence rates compared with chemotherapy in a communitybased setting. 11, 27 Our data demonstrate the stable receipt of chemotherapy for men with CSIA NSGCT and increased receipt for men with CSIB NSGCT. Chemotherapy receipt was low in the years 2012 and 2013 for CSIA NSGCT and was <33% among men with CSIB NSGCT. In addition to the concurrent trends in the use of surveillance, these findings may further indicate the acceptance of riskadapted management for patients with and without Original Article lymphovascular invasion based on long-term follow-up from European trials in support of this approach. 20, 21 Although it is not possible to determine chemotherapy type from the NCDB, 1 population-based study from the United States demonstrated that combined cisplatin, etoposide, and bleomycin was used in 75% of patients who received chemotherapy in 1999. 12 Although our survival analysis was limited to overall survival, and not cancer-specific survival, as expected, the results for this large cohort demonstrated similarly high survival rates for each postorchiectomy management strategy.
Strengths of our study include the size of our contemporary cohort, which is the largest of its type for NSGCT. In addition, the NCDB provides valuable information on chemotherapy use, chemotherapy receipt date, and several other variables, such as comorbidities, which are not available in SEER or other databases.
Our observational study has limitations. The study is subject to selection bias, because all patients underwent orchiectomy and were treated at Commission on Canceraccredited hospitals. In addition, we are unable to account for unmeasured variables. The NCDB lacks information on compliance with surveillance imaging, tumor markers, and clinical follow-up; therefore, we are unable to include these measures as part of our definition of surveillance. We likely underestimated the number of patients who opted for surveillance, because some patients who received surveillance may have had disease recurrences and subsequently may have undergone RPLND or received chemotherapy. However, the use of RPLND after initial surveillance for clinical stage I NSGCT is extremely low (2% in 1 large retrospective series). 19 Although most men receive chemotherapy after recurrence, 19 very few relapses are discovered within 60 days of orchiectomy, 15, 16 possibly because of the schedules for surveillance protocols. Delaying postorchiectomy chemotherapy this long would be unusual, and categorizing these patients as having received chemotherapy did not change the surveillance rates substantially. 
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